(VIANEWS) – Golden Ocean Group Limited (GOGL), Chesapeake Utilities Corporation (CPK), Amgen (AMGN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Golden Ocean Group Limited (GOGL)
43.5% sales growth and 9.83% return on equity
Golden Ocean Group Limited, a shipping company, owns and operates a fleet of dry bulk vessels comprising Newcastlemax, Capesize, Panamax, and Ultramax vessels worldwide. It owns and operates dry bulk vessels in the spot and time charter markets. The company transports bulk commodities, such as ores, coal, grains, and fertilizers. As of March 18, 2021, it owned a fleet of 67 dry bulk vessels. Golden Ocean Group Limited is based in Hamilton, Bermuda.
Earnings Per Share
As for profitability, Golden Ocean Group Limited has a trailing twelve months EPS of $0.93.
PE Ratio
Golden Ocean Group Limited has a trailing twelve months price to earnings ratio of 14.94. Meaning, the purchaser of the share is investing $14.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.83%.
2. Chesapeake Utilities Corporation (CPK)
37.2% sales growth and 9.07% return on equity
Chesapeake Utilities Corporation operates as an energy delivery company. The Regulated Energy segment engages in the natural gas distribution operations in central and southern Delaware, Maryland's eastern shore, and Florida; regulated natural gas transmission in the Delmarva Peninsula and Florida; and regulated electric distribution in northeast and northwest Florida. The Unregulated Energy segment engages in the propane operations in the Mid-Atlantic region and Florida; unregulated natural gas transmission/supply operation in central and eastern Ohio; generation of electricity and steam; and provision of compressed natural gas, liquefied natural gas, and renewable natural gas transportation and pipeline solutions primarily to utilities and pipelines in the eastern United States. This segment also provides other unregulated energy services, such as energy-related merchandise sales; heating, ventilation, and air conditioning services; and plumbing and electrical services. The company was founded in 1859 and is headquartered in Dover, Delaware.
Earnings Per Share
As for profitability, Chesapeake Utilities Corporation has a trailing twelve months EPS of $4.76.
PE Ratio
Chesapeake Utilities Corporation has a trailing twelve months price to earnings ratio of 22.66. Meaning, the purchaser of the share is investing $22.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.07%.
Volume
Today’s last reported volume for Chesapeake Utilities Corporation is 57603 which is 41.7% below its average volume of 98811.
3. Amgen (AMGN)
22.2% sales growth and 72.57% return on equity
In May, Amgen said it was very encouraged with the interim data from the phase II study on MariTide.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Earnings Per Share
As for profitability, Amgen has a trailing twelve months EPS of $12.48.
PE Ratio
Amgen has a trailing twelve months price to earnings ratio of 21.42. Meaning, the purchaser of the share is investing $21.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 72.57%.
Yearly Top and Bottom Value
Amgen’s stock is valued at $267.28 at 16:22 EST, way under its 52-week high of $329.72 and way above its 52-week low of $218.61.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 16, 2024, the estimated forward annual dividend rate is 9 and the estimated forward annual dividend yield is 2.9%.
Volume
Today’s last reported volume for Amgen is 1865240 which is 36.92% below its average volume of 2957370.
Sales Growth
Amgen’s sales growth is 18.9% for the present quarter and 22.2% for the next.
Previous days news about Amgen(AMGN)
- According to Zacks on Tuesday, 9 July, "Based on the success seen by Lilly and Novo in the obesity space, several other companies like Viking Therapeutics (VKTX Quick QuoteVKTX – Free Report) , Amgen (AMGN Quick QuoteAMGN – Free Report) and Roche are also developing their obesity drugs in clinical studies.", "Based on these results, Amgen also initiated activities to expand manufacturing capacity for the drug."
4. Middlesex Water Company (MSEX)
14.6% sales growth and 8.7% return on equity
Middlesex Water Company owns and operates regulated water utility and wastewater systems. It operates in two segments, Regulated and Non-Regulated. The Regulated segment collects, treats, and distributes water on a retail and wholesale basis to residential, commercial, industrial, and fire protection customers in parts of New Jersey, Delaware, and Pennsylvania. This segment also includes regulated wastewater systems in New Jersey and Delaware. The Non-Regulated segment provides non-regulated contract services for the operation and maintenance of municipal and private water and wastewater systems in New Jersey and Delaware. The company was incorporated in 1896 and is headquartered in Iselin, New Jersey.
Earnings Per Share
As for profitability, Middlesex Water Company has a trailing twelve months EPS of $2.02.
PE Ratio
Middlesex Water Company has a trailing twelve months price to earnings ratio of 27.05. Meaning, the purchaser of the share is investing $27.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.7%.
Moving Average
Middlesex Water Company’s value is above its 50-day moving average of $53.49 and below its 200-day moving average of $57.95.
Volume
Today’s last reported volume for Middlesex Water Company is 38996 which is 66.56% below its average volume of 116642.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 16.4% and 19.6%, respectively.
5. Synopsys (SNPS)
8.6% sales growth and 21.58% return on equity
Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. It operates in three segments: Design Automation, Design IP, and Software Integrity. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions. It also provides intellectual property (IP) solutions for USB, PCI Express, DDR, Ethernet, MIPI, HDMI, and Bluetooth low energy applications; logic libraries and embedded memories; processor cores, software, and application-specific instruction-set processor tools for embedded applications; security IP solutions; IP solutions for automotive market; and system-on-chip (SoC) infrastructure IP, datapath and building block IP, and verification IP products, as well as mathematical and floating-point components, and Arm AMBA interconnect fabric and peripherals. In addition, the company offers HAPS FPGA-based prototyping systems; virtual prototyping solutions; and Platform Architect solutions for SoC architecture analysis and optimization, as well as optical products, and mechatronic simulations. Further, it provides security and quality testing products, managed services, programs and professional services, and training that enable its customers to detect and remediate security vulnerabilities, and defects in the software development lifecycle, as well as manufacturing solutions. Additionally, the company provides intelligent orchestration solution, software risk manager, and black duck software composition analysis tools. It serves electronics, financial services, automotive, medicine, energy, and industrial areas. The company was incorporated in 1986 and is headquartered in Sunnyvale, California.
Earnings Per Share
As for profitability, Synopsys has a trailing twelve months EPS of $9.04.
PE Ratio
Synopsys has a trailing twelve months price to earnings ratio of 61.63. Meaning, the purchaser of the share is investing $61.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.58%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 19.7% and 10.2%, respectively.
Previous days news about Synopsys(SNPS)
- Brokers suggest investing in synopsys (snps): read this before placing a bet. According to Zacks on Thursday, 11 July, "Let’s take a look at what these Wall Street heavyweights have to say about Synopsys (SNPS Quick QuoteSNPS – Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.", "Check price target & stock forecast for Synopsys here>>>The ABR suggests buying Synopsys, but making an investment decision solely on the basis of this information might not be a good idea. "
6. U.S. Physical Therapy (USPH)
7.6% sales growth and 6.47% return on equity
U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The company operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. It offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. The company was founded in 1990 and is based in Houston, Texas.
Earnings Per Share
As for profitability, U.S. Physical Therapy has a trailing twelve months EPS of $1.16.
PE Ratio
U.S. Physical Therapy has a trailing twelve months price to earnings ratio of 79.53. Meaning, the purchaser of the share is investing $79.53 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.47%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 7.9% and 21%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.8%, now sitting on 605.68M for the twelve trailing months.
Sales Growth
U.S. Physical Therapy’s sales growth for the next quarter is 7.6%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 22, 2024, the estimated forward annual dividend rate is 1.76 and the estimated forward annual dividend yield is 1.91%.
